Divis Laboratories Ltd logo

Divis Laboratories Ltd

DIVISLAB NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
2.3L Cr
Volatility
High Risk
P/E Ratio
77.95
EBITDA
₹3,948 Cr
Return on Equity
15.32%
Debt to Equity
0
Book Value
₹631.38
EPS
₹63.06
52W High
₹8,674
52W Low
₹5,636.5

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Divis Laboratories Ltd insights

41 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.0%

Weaknesses

2
  • Stock is trading at 13.4 times its book value
  • The company has delivered a poor sales growth of 8.67% over past five years.

Growth Rate

Revenue Growth
13.95% ↗
Net Income Growth
17.21% ↘
Cash Flow Change
65.64% ↗
ROE
4.64% ↘
ROCE
0.58% ↘
EBITDA Margin (Avg.)
4.36% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Divis Laboratories trades at a market cap of ~₹2.25 lakh crore with a PE of 77.6x and PB of 13.5x, reflecting premium valuations. The company delivered 29% TTM profit growth and 16% TTM sales growth, is virtually debt-free, and is seeing its custom synthesis segment cross 50% of revenue with 44% YoY growth in Q3 FY25. However, its 5-year sales CAGR of 9% and elevated valuation multiples remain key considerations.

Bull Case 8
  • Virtually debt-free balance sheet provides financial flexibility and low interest burden, enabling reinvestment into capacity expansion at Kakinada
  • Custom synthesis segment grew 44% YoY in Q3 FY25 and now contributes over 51% of revenue, up from ~40% in FY21, with higher margins above 40%
  • TTM profit growth of 29% significantly outpaces the 10-year profit CAGR of 9%, indicating an earnings acceleration cycle
  • FY25 full-year PAT of ₹2,191 crore vs ₹1,600 crore in FY24, a 37% YoY jump, with PBT rising from ₹2,163 crore to ₹2,916 crore
  • EBITDA margin expanded 568 bps YoY to 32% in Q3 FY25, with operating profit margin reaching ~34% in Q4 FY25, showing structural margin improvement
  • Consistent dividend payout of 39% and declared ₹30/share dividend in Q4 FY25, reflecting shareholder-friendly capital allocation
  • Stock CAGR of 41% over the past 1 year and 22% over 10 years demonstrates long-term wealth creation track record
  • Rising RFPs (Request for Proposals) in custom synthesis and pipeline of 10+ new generic molecules coming off-patent in 2025-26 provide revenue visibility
Bear Case 8
  • PE of 77.6x is significantly elevated relative to the 10-year profit CAGR of 9%, implying the stock prices in substantial future growth
  • Trading at 13.5x book value leaves limited margin of safety if growth disappoints or margins compress
  • 5-year compounded sales growth of only 9% and reported 5-year sales growth of 8.67% indicate historically modest top-line expansion
  • 5-year compounded profit CAGR of just 6% suggests the recent 29% TTM growth may not be sustainable at these levels
  • ROE of 15-17% over 3-5 years is respectable but not exceptional for a stock commanding 77x earnings
  • Dividend yield of only 0.35% offers negligible income cushion at current valuations
  • Heavy dependence on global pharma supply chain dynamics and USD-denominated export revenue exposes the company to currency and geopolitical risks
  • Kakinada capacity expansion requires multi-year capex with commercial ramp expected only in FY26-27, creating near-term execution risk

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 20h ago
Neutral 3
  • Q1 FY27 earnings call audio posted Aug 1

    Divis Labs uploaded the audio recording of its Q1 FY27 earnings conference call held on August 01, 2026, to its website for investor access.

  • Two senior VPs retire Jul 31

    L. Ramesh Babu and D. Madhu Babu retired as Senior Management Personnel effective July 31, 2026, disclosed under SEBI LODR Regulation 30.

  • Q1 FY27 earnings call scheduled Jul 24

    Divi's Laboratories scheduled an earnings conference call on August 01, 2026 at 14:00 IST to discuss unaudited results for the quarter ended June 30, 2026.

TL;DR: Recent news flow for Divis Laboratories is purely procedural — an earnings call schedule, its audio upload, and two senior VP retirements. There are no material positives or headwinds emerging from these disclosures. Investors should watch for the actual Q1 FY27 financial results and any strategic commentary from the earnings call for directional cues.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,778
1,909
1,855
2,303
2,118
2,338
2,319
2,585
2,410
2,715
2,604
2,831
3,080
Expenses
1,274
1,430
1,366
1,572
1,496
1,622
1,576
1,699
1,681
1,827
1,714
1,897
1,825
Operating Profit
504
479
489
731
622
716
743
886
729
888
890
934
1,255
OPM %
28%
25%
26%
32%
29%
31%
32%
34%
30%
33%
34%
33%
41%
Other Income
81
86
95
79
79
106
82
86
119
145
14
155
64
Interest
0
1
0
2
0
1
0
1
3
8
6
6
6
Depreciation
93
95
95
95
97
99
99
107
112
113
118
120
133
PBT
492
469
489
713
604
722
726
864
733
912
780
963
1,180
Tax %
28%
26%
27%
25%
29%
29%
19%
23%
26%
24%
25%
22%
24%
Net Profit
356
348
358
538
430
510
589
662
545
689
583
751
902
EPS in Rs
13.41
13.11
13.49
20.27
16.2
19.21
22.19
24.94
20.53
25.95
21.96
28.29
33.98
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,115
3,776
4,064
3,891
4,946
5,394
6,969
8,960
7,768
7,845
9,360
10,560
11,230
Expenses
1,942
2,354
2,615
2,622
3,072
3,568
4,102
5,075
5,397
5,635
6,387
7,118
7,263
Operating Profit
1,173
1,423
1,450
1,269
1,874
1,826
2,867
3,885
2,370
2,210
2,973
3,442
3,967
OPM %
38%
38%
36%
33%
38%
34%
41%
43%
31%
28%
32%
33%
35%
Other Income
38
93
72
107
154
186
57
112
344
335
348
433
378
Interest
3
5
3
2
5
7
2
2
2
4
3
24
26
Depreciation
136
118
123
142
169
186
256
312
343
378
402
463
484
PBT
1,072
1,393
1,395
1,231
1,855
1,819
2,666
3,684
2,369
2,163
2,916
3,388
3,835
Tax %
21%
19%
24%
29%
27%
24%
26%
20%
23%
26%
25%
24%
—
Net Profit
852
1,126
1,060
877
1,353
1,377
1,984
2,960
1,823
1,600
2,191
2,568
2,925
EPS in Rs
32.07
42.41
39.95
33.04
50.96
51.85
74.75
112
68.69
60.27
82.53
96.73
110
Div. Payout %
31%
24%
25%
30%
31%
31%
27%
27%
44%
50%
36%
31%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
27
53
53
53
53
53
53
53
53
53
53
53
Reserves
3,469
4,240
5,304
5,872
6,904
7,257
9,242
11,675
12,714
13,518
14,916
16,708
Borrowings
27
42
36
63
106
39
5
4
3
3
4
7
Other Liabilities
883
562
762
797
973
1,183
1,471
1,628
1,654
1,886
1,948
3,251
Total Liabilities
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Fixed Assets
1,309
1,439
1,559
1,996
2,088
2,782
3,704
4,325
4,723
4,739
5,442
6,528
CWIP
218
264
444
120
492
920
711
470
212
778
1,022
2,113
Investments
733
803
1,631
1,889
1,946
971
0
72
77
82
65
69
Other Assets
2,145
2,392
2,521
2,780
3,511
3,858
6,356
8,493
9,413
9,861
10,392
11,309
Total Assets
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
826
1,038
1,150
776
954
1,216
1,947
1,912
2,460
1,261
1,653
2,738
Investing
-521
-406
-1,140
-478
-685
-83
75
-2,195
-2,708
-269
-804
-2,219
Financing
-303
-631
2
-314
-246
-1,091
-35
-532
-797
-799
-799
-804
Net Cash Flow
3
0
13
-17
23
41
1,987
-816
-1,045
193
50
-285
Free Cash Flow
519
642
774
502
221
33
1,037
1,199
1,987
258
215
221
CFO/OP
88
91
100
82
77
91
90
66
124
74
83
105
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
85
81
95
86
96
88
99
84
100
106
103
Inventory Days
350
293
307
314
347
316
329
341
352
364
311
346
Days Payable
68
56
104
96
96
100
117
96
89
94
88
106
Cash Conversion Cycle
368
322
284
313
336
312
300
344
347
370
330
343
Working Capital Days
140
158
147
176
169
180
152
177
188
206
192
195
ROCE %
33%
36%
29%
22%
29%
25%
32%
35%
19%
16%
20%
22%

Shareholding Pattern

As of Jun 2026
Promoters 51.88%
FIIs 20.20%
DIIs 19.38%
Public 6.41%
Others 2.13%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
51.95%
51.95%
51.95%
51.95%
51.94%
51.94%
51.94%
51.94%
51.94%
51.93%
51.93%
51.92%
51.92%
51.90%
51.89%
51.89%
51.89%
51.89%
51.89%
51.88%
51.88%
51.88%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
14.86%
14.68%
16.16%
17.25%
17.99%
18.01%
19.74%
19.39%
20.08%
20.29%
20.20%
DIIs
12.64%
12.61%
12.64%
13.40%
13.73%
13.93%
19.54%
20.67%
21.07%
21.23%
20.97%
21.88%
22.21%
21.77%
21.06%
20.54%
20.71%
19.05%
19.76%
19.28%
19.22%
19.38%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
9.28%
8.81%
8.87%
9.01%
9.27%
9.53%
9.20%
9.53%
9.61%
9.28%
9.02%
8.85%
8.69%
7.77%
7.41%
7.32%
7.17%
7.05%
6.78%
6.61%
6.48%
6.41%
Others
26.14%
26.64%
26.55%
25.64%
25.06%
24.59%
19.31%
17.86%
17.37%
17.56%
18.08%
2.48%
2.50%
2.41%
2.39%
2.26%
2.22%
2.27%
2.18%
2.15%
2.13%
2.13%
No. of Shareholders
2,08,203
1,93,883
2,23,403
2,74,505
3,09,397
3,46,905
3,79,257
4,14,847
4,33,621
4,02,155
3,73,860
3,54,482
3,47,629
2,98,310
2,78,899
2,80,601
2,67,755
2,59,825
2,49,634
2,33,844
2,28,006
2,26,324

Documents

Frequently Asked Questions about Divis Laboratories Ltd

What does Divis Laboratories Ltd do?
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Where is Divis Laboratories Ltd (DIVISLAB) listed?
Divis Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: DIVISLAB and BSE: 532488. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Divis Laboratories Ltd belong to?
Divis Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Divis Laboratories Ltd?
Divis Laboratories Ltd has a market capitalisation of approximately ₹228594.99 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Divis Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd is 77.95. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Divis Laboratories Ltd?
Over the past 52 weeks, Divis Laboratories Ltd has traded between a low of ₹5,636.5 and a high of ₹8,674. This range helps investors understand the stock's price volatility and recent trading levels.
Does Divis Laboratories Ltd pay dividends?
Yes, Divis Laboratories Ltd has a dividend yield of 0.35%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Divis Laboratories Ltd?
Divis Laboratories Ltd has a Return on Equity (ROE) of 15.32%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Divis Laboratories Ltd on Tapetide?
On Tapetide, you can view Divis Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Website divislabs.com
CEO Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Employees 10,542
Listed 2003-03-12
Face Value ₹ 2
Issued Size 26,54,68,580

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List